Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00163/full |
| _version_ | 1819327369339469824 |
|---|---|
| author | Timothy M. Pierpont Candice B. Limper Kristy L. Richards Kristy L. Richards |
| author_facet | Timothy M. Pierpont Candice B. Limper Kristy L. Richards Kristy L. Richards |
| author_sort | Timothy M. Pierpont |
| collection | DOAJ |
| description | Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval in 1997, it has improved outcomes in all B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from in vitro studies while the roles of the various response mechanisms in humans are still largely undetermined. Polymorphisms in Fc gamma receptor and complement protein genes have been implicated as potential predictors of differential response to rituximab, but have not yet shown sufficient influence to impact clinical decisions. Unlike most targeted therapies developed today, no known biomarkers to indicate target engagement/tumor response have been identified, aside from reduced tumor burden. The lack of companion biomarkers beyond CD20 itself has made it difficult to predict which patients will respond to any given anti-CD20 antibody. In the past decade, two new anti-CD20 antibodies have been approved: ofatumumab, which binds a distinct epitope of CD20, and obinutuzumab, a mAb derived from rituximab with modifications to the Fc portion and to its glycosylation. Both are fully humanized and have biological activity that is distinct from that of rituximab. In addition to these new anti-CD20 antibodies, another imminent change in targeted lymphoma treatment is the multitude of biosimilars that are becoming available as rituximab’s patent expires. While the widespread use of rituximab itself will likely continue, its biosimilars will increase global access to the therapy. This review discusses current research into mechanisms and potential biomarkers of rituximab response, as well as its biosimilars and the newer CD20 binding mAb therapies. Increased ability to assess the effectiveness of rituximab in an individual patient, along with the availability of alternative anti-CD20 antibodies will likely lead to dramatic changes in how we use CD20 antibodies going forward. |
| first_indexed | 2024-12-24T13:09:45Z |
| format | Article |
| id | doaj.art-b75208d6641e4b62be73c3099d58aef3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T13:09:45Z |
| publishDate | 2018-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b75208d6641e4b62be73c3099d58aef32022-12-21T16:53:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-06-01810.3389/fonc.2018.00163359740Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody TherapyTimothy M. Pierpont0Candice B. Limper1Kristy L. Richards2Kristy L. Richards3Richards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United StatesRichards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United StatesRichards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United StatesDepartment of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United StatesRituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval in 1997, it has improved outcomes in all B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from in vitro studies while the roles of the various response mechanisms in humans are still largely undetermined. Polymorphisms in Fc gamma receptor and complement protein genes have been implicated as potential predictors of differential response to rituximab, but have not yet shown sufficient influence to impact clinical decisions. Unlike most targeted therapies developed today, no known biomarkers to indicate target engagement/tumor response have been identified, aside from reduced tumor burden. The lack of companion biomarkers beyond CD20 itself has made it difficult to predict which patients will respond to any given anti-CD20 antibody. In the past decade, two new anti-CD20 antibodies have been approved: ofatumumab, which binds a distinct epitope of CD20, and obinutuzumab, a mAb derived from rituximab with modifications to the Fc portion and to its glycosylation. Both are fully humanized and have biological activity that is distinct from that of rituximab. In addition to these new anti-CD20 antibodies, another imminent change in targeted lymphoma treatment is the multitude of biosimilars that are becoming available as rituximab’s patent expires. While the widespread use of rituximab itself will likely continue, its biosimilars will increase global access to the therapy. This review discusses current research into mechanisms and potential biomarkers of rituximab response, as well as its biosimilars and the newer CD20 binding mAb therapies. Increased ability to assess the effectiveness of rituximab in an individual patient, along with the availability of alternative anti-CD20 antibodies will likely lead to dramatic changes in how we use CD20 antibodies going forward.https://www.frontiersin.org/article/10.3389/fonc.2018.00163/fullrituximablymphomacancerimmunotherapymonoclonal antibody |
| spellingShingle | Timothy M. Pierpont Candice B. Limper Kristy L. Richards Kristy L. Richards Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy Frontiers in Oncology rituximab lymphoma cancer immunotherapy monoclonal antibody |
| title | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy |
| title_full | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy |
| title_fullStr | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy |
| title_full_unstemmed | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy |
| title_short | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy |
| title_sort | past present and future of rituximab the world s first oncology monoclonal antibody therapy |
| topic | rituximab lymphoma cancer immunotherapy monoclonal antibody |
| url | https://www.frontiersin.org/article/10.3389/fonc.2018.00163/full |
| work_keys_str_mv | AT timothympierpont pastpresentandfutureofrituximabtheworldsfirstoncologymonoclonalantibodytherapy AT candiceblimper pastpresentandfutureofrituximabtheworldsfirstoncologymonoclonalantibodytherapy AT kristylrichards pastpresentandfutureofrituximabtheworldsfirstoncologymonoclonalantibodytherapy AT kristylrichards pastpresentandfutureofrituximabtheworldsfirstoncologymonoclonalantibodytherapy |